On April 3rd, Recro Pharma (REPH) publicized its decision to cut operating expenses at its Acute Care Segment by reducing employee headcount by 50. This is in reaction to the company receiving its second CRL from the FDA concerning its IV Meloxicam candidate. This strategy intends to decrease the cash burn for 2019 while preserving its prosperous CDMO segment. As a result, management expects these actions will lead to the company hitting break-even in Q3 and potentially cash flow positive at some point in 2H of 2019. With regards to Meloxicam, Recro still anticipates the